Expanded Mutation Profiling in Appendix Peritoneal Metastasis Has Prognostic and Therapeutic Utility When Managed with Cytoreductive Surgery/ Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)

Authors

Chunmeng Zhang, University of Nebraska Medical CenterFollow
Ben Plambeck, University of Nebraska Medical Center
Maggie Moore, University of Nebraska Medical Center
Alexander Tu, University of Nebraska Medical Center
Ryan Miku, University of Nebraska Medical Center
Valerie Shostrom, University of Nebraska Medical CenterFollow
Krista Brown, University of Nebraska Medical CenterFollow
Allison Cushman-Volkoun, University of Nebraska Medical CenterFollow
Benjamin Swanson, University of Nebraska Medical CenterFollow
Jason Foster, University of Nebraska Medical CenterFollow

Document Type

Conference Proceeding

Disciplines

Higher Education | Medicine and Health Sciences

DOI

10.32873/unmc.dc.gmerj.2.1.030

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Recommended Citation

Zhang, C., Plambeck, B., Moore, M., Tu, A., Miku, R., Shostrom, V., Brown, K., Cushman-Volkoun, A., Swanson, B., , Foster, J. Expanded Mutation Profiling in Appendix Peritoneal Metastasis Has Prognostic and Therapeutic Utility When Managed with Cytoreductive Surgery/ Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). Graduate Medical Education Research Journal. 2020 Sep 29; 2(1).
https://digitalcommons.unmc.edu/gmerj/vol2/iss1/31